Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Aldeyra Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
ALDX
Nasdaq
8731
https://www.aldeyra.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Aldeyra Therapeutics Inc
Aldeyra Therapeutics Inc President and CEO Todd Brady Sells Company Shares
- Mar 13th, 2024 6:33 am
Here's Why You Should Invest in Aldeyra (ALDX) Stock Now
- Mar 6th, 2024 2:40 pm
Is Aclaris Therapeutics (ACRS) Outperforming Other Medical Stocks This Year?
- Mar 4th, 2024 2:40 pm
Zacks Industry Outlook Highlights United Therapeutics, Esperion Therapeutics., Heron Therapeutics, Lyra Therapeutics and Aldeyra Therapeutics
- Mar 1st, 2024 2:45 pm
5 Small Drug Stocks to Buy From a Rebounding Industry
- Feb 29th, 2024 1:53 pm
Institutions own 37% of Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) shares but retail investors control 37% of the company
- Feb 22nd, 2024 12:35 pm
Aldeyra Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
- Feb 6th, 2024 12:00 pm
Aldeyra Therapeutics Provides Clinical and Regulatory Update and Announces Advancement of RASP Platform in Systemic and Retinal Inflammatory Diseases
- Jan 4th, 2024 12:00 pm
Aldeyra Therapeutics Announces Statistically and Clinically Significant Improvement from Baseline in Phase 2 Clinical Trial of ADX‑629 in Patients with Atopic Dermatitis
- Dec 19th, 2023 12:00 pm
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from Phase 2 Clinical Trial of ADX-629 in Patients with Atopic Dermatitis
- Dec 18th, 2023 9:01 pm
13 Hot Penny Stocks To Buy According to Hedge Funds
- Dec 6th, 2023 4:55 pm
Semtech (SMTC) to Release Q3 Earnings: What's in the Cards?
- Dec 5th, 2023 6:59 pm
Should You Buy Aldeyra Therapeutics (ALDX) Ahead of Earnings?
- Dec 5th, 2023 2:00 pm
Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Dry Eye Disease
- Nov 27th, 2023 9:07 pm
Aldeyra Therapeutics Enters into Exclusive Option Agreement with AbbVie for License to Develop and Commercialize Reproxalap
- Nov 1st, 2023 11:05 am
Biotech Stock Roundup: ALDX, EVLO Down on Setback, SRRK Offers Updates & More
- Oct 18th, 2023 12:30 pm
Aldeyra (ALDX) Plummets on Dry Eye Disease Drug's Setback
- Oct 17th, 2023 2:13 pm
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) has caught the attention of institutional investors who hold a sizeable 43% stake
- Sep 15th, 2023 10:50 am
15 Most Shorted Stocks That Are Loved By Analysts
- Aug 28th, 2023 2:22 pm
Can Aldeyra Therapeutics, Inc. (ALDX) Climb 107.66% to Reach the Level Wall Street Analysts Expect?
- Jul 20th, 2023 1:55 pm
Scroll